A tale of two vac­cines: As­traZeneca's shot still a block­buster, but Pfiz­er sales are on an­oth­er lev­el

With As­traZeneca’s sec­ond quar­ter earn­ings call Thurs­day morn­ing came up­dat­ed sales num­bers for its Covid-19 vac­cine — and com­pared to the big mR­NA play­ers, the num­bers pale in com­par­i­son.

The British-Swedish drug­mak­er re­port­ed its Covid-19 jab has raked in about $1.17 bil­lion glob­al­ly in the first half, in­clud­ing $894 mil­lion in the sec­ond quar­ter alone. Pfiz­er, mean­while, has seen sky­rock­et­ing growth of its vac­cine with $3.5 bil­lion in sales in the first quar­ter and an­oth­er $7.8 bil­lion in the sec­ond quar­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER